The Johnson & Johnson COVID Vaccine Halt: Here's What Investors Need to Know
Johnson & Johnson (NYSE: JNJ) has what many Americans want: a one-dose COVID-19 vaccine. I know people who waited on vaccination specifically to get the J&J jab. The U.S. Food and Drug Administration (FDA) granted the company Emergency Use Authorization in late February. That's two months after the authorization of two-dose vaccines from Pfizer and Moderna. And last month the U.S. ordered an additional 100 million J&J doses. It ordered an initial 100 million doses last year.
The momentum slammed to a halt this week, though. The FDA and the Centers for Disease Control and Prevention (CDC) recommended a pause in administration of the J&J vaccine after the occurrence of "rare and severe" blood clots in some people. Now investors may be wondering what this means for J&J's future in the vaccine space -- and its share price. Here's what you need to know.
Image source: Getty Images.
Source Fool.com
